Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Purple Biotech Ltd ADR (NQ: PPBT )

0.5540 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9
Open 0.5540
Bid (Size) 0.5010 (1)
Ask (Size) 0.5609 (1)
Prev. Close 0.5540
Today's Range 0.5540 - 0.5540
52wk Range 0.3023 - 1.800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
From Purple Biotech Ltd.
Via GlobeNewswire

Performance

YTD
-28.11%
-28.11%
1 Month
+21.76%
+21.76%
3 Month
-19.73%
-19.73%
6 Month
-44.60%
-44.60%
1 Year
-65.38%
-65.38%

More News

Read More
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech: Q3 Earnings Insights
Via Benzinga
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
From Purple Biotech Ltd.
Via GlobeNewswire
PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
Via InvestorPlace
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Purple Biotech Fortifies NT219 Patent Protection
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Purple Biotech Announces $5 Million Registered Direct Offering
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Second Quarter 2023 Financial Results
From Purple Biotech Ltd.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.